NCT02807363 - A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

June 27, 2018

Study Completion Date

June 27, 2018

Conditions

Endometriosis

Interventions

DRUG

Leuprolide Oral Tablet 4-mg QD

4-mg Leuprolide oral tablet once daily for 28 consecutive days.

DRUG

Leuprolide Oral Tablet 4-mg BID

4-mg Leuprolide oral tablet twice daily for 28 consecutive days.

DRUG

Leuprolide Depot

3.75 mg intramuscular depot injection

DRUG

Leuprolide Oral Tablet 10-mg BID

10-mg Leuprolide oral tablet twice daily for 28 consecutive days.

Trial Locations (1)

inVentiv Health Clinique, Inc., Québec